Nomogram for predicting survival for patients receiving definitive chemoradiation in locally advanced squamous cell carcinoma of the head and neck: A secondary analysis of NRG/RTOG 0129, 0522, and 1016


1 Radiation Oncology, University Hospitals/Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA, 2 Biostatistics, University Hospitals/Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA, 3 Statistics and Data Management Center, NRG Oncology, Philadelphia, PA, USA, 4 Biostatistics and Bioinformatics, Case Comprehensive Cancer Center, Cleveland, OH, USA, 5 Radiation Oncology, The Pennsylvania State Cancer Institute, Hershey, PA, USA, 6 Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA, 7 Radiation Oncology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA, 8 Radiation Oncology, H. Lee Moffitt Cancer Center University of South Florida, Tampa, FL, USA, 9 Radiation Oncology, Sutter Cancer Research Consortium, Sacramento, CA, USA, 10 Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA, 11 Radiation Oncology, Notre Dame du CHUM, Montreal, QC, Canada, 12 Radiation Oncology, Emory University, Atlanta, GA, USA, 13 Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Background

The prognostic implication of HPV-mediated head and neck squamous cell carcinoma (HNSCC) is changing the approach to this disease in the cisplatin-based chemoradiation era. More recent trials provide new data to analyze factors influencing survival in this cohort. We aimed to find prognostic factors for survival in patients with HNSCC, assess outcomes by sex, and generate nomograms using data from 3 randomized trials.

Methods

This secondary analysis of 3 phase III randomized trials included patients age 18+ with pathologically confirmed HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx. Training data from RTOG 0522/1016 were used to generate 3 models using different analytic approaches for both overall survival (OS) and progression-free survival (PFS) that were internally validated using cross-validation. The models with the highest C-indices were the Cox proportional hazards (CPH) models, which were then externally validated using data from RTOG 0129. Nomograms for OS and PFS at 2, 3, and 5 years were generated. Substaging for T/N categories was excluded to minimize heterogeneity between AJCC staging editions.

Results

721 patients from RTOG 0129, 891 from 0522, and 406 from 1016 met criteria for inclusion. The final multivariable CPH models for OS and PFS included age, sex, race, smoking history, primary site, p16 status, T category, N category, anemia (hemoglobin <= 13.5 g/dL for males, <= 12.5 g/dL for females), and Zubrod performance status. Nomograms to predict OS and PFS will be made publicly accessible at the time of manuscript publication. Both nomograms showed moderate to high predictive accuracy on validation dataset (C-index: OS 0.70, PFS 0.68).

Conclusions

Using a large cohort from 3 randomized trials of HNSCC patients receiving cisplatin-based chemoradiation, we developed internally and independently validated nomograms for prognostication of outcomes for individual patients using pretreatment clinical and patient characteristics. There was no association of sex with OS or PFS. To facilitate use and further validation of our nomograms, a free web-based tool is made available.

Legal entity responsible for the study

The authors.

Funding

NRG Oncology.

Disclosure

M. Machtay: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Institutional, Research Grant:
AstraZeneca. J. Caudell: Financial Interests, Personal, Research Grant, Grants and Honoraria: Varian Medical Systems. All other authors have declared no conflicts of interest.

© European Society for Medical Oncology